HU223313B1 - Kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents
Kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra Download PDFInfo
- Publication number
- HU223313B1 HU223313B1 HU9802839A HUP9802839A HU223313B1 HU 223313 B1 HU223313 B1 HU 223313B1 HU 9802839 A HU9802839 A HU 9802839A HU P9802839 A HUP9802839 A HU P9802839A HU 223313 B1 HU223313 B1 HU 223313B1
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- quinazoline
- chloro
- fluoroanilino
- pharmaceutically acceptable
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 230000008569 process Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- -1 3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2- ( 4-methylpiperazin-1-yl) ethoxy, 2- (imidazol-1-yl) ethoxy, 3- (imidazol-1-yl) propoxy Chemical group 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 5
- 150000003246 quinazolines Chemical class 0.000 claims description 39
- 239000002253 acid Substances 0.000 claims description 17
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- STNFCUFBMSVMBL-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-morpholin-4-ylethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 STNFCUFBMSVMBL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- JACDFLVHUYYSBS-UHFFFAOYSA-N n-(3,4-difluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 JACDFLVHUYYSBS-UHFFFAOYSA-N 0.000 claims description 3
- BQTOLZHBHCEHJX-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BQTOLZHBHCEHJX-UHFFFAOYSA-N 0.000 claims description 3
- BLFAAYGECSULMU-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BLFAAYGECSULMU-UHFFFAOYSA-N 0.000 claims description 3
- IFIRBZOPPUFQRQ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-piperidin-1-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IFIRBZOPPUFQRQ-UHFFFAOYSA-N 0.000 claims description 3
- XGPAXWVNLWKLEF-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGPAXWVNLWKLEF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- JJKSOLDGGFGXJF-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[3-(diethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 JJKSOLDGGFGXJF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 97
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 35
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 27
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 25
- 239000002244 precipitate Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- JLVTVCRXFMLUIF-UHFFFAOYSA-N O-Desmorpholinopropyl Gefitinib Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JLVTVCRXFMLUIF-UHFFFAOYSA-N 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 13
- 101800003838 Epidermal growth factor Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229940116977 epidermal growth factor Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102400001368 Epidermal growth factor Human genes 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- KOBGVRFQJWPUFX-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCBr)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 KOBGVRFQJWPUFX-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- CZORGPPUWMSETM-UHFFFAOYSA-N 4-(3,4-difluoroanilino)-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 CZORGPPUWMSETM-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- ALIORLVEFABXRY-UHFFFAOYSA-N 1-(3-chloropropyl)imidazole Chemical compound ClCCCN1C=CN=C1 ALIORLVEFABXRY-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- BPDYNSGBOYVXBT-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F BPDYNSGBOYVXBT-UHFFFAOYSA-N 0.000 description 4
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- DSYIUUXIRMLRQU-UHFFFAOYSA-N (4-chloro-7-methoxyquinazolin-6-yl) acetate;hydrochloride Chemical compound Cl.C1=NC(Cl)=C2C=C(OC(C)=O)C(OC)=CC2=N1 DSYIUUXIRMLRQU-UHFFFAOYSA-N 0.000 description 3
- SOLQIFINSOHAQD-UHFFFAOYSA-N (7-methoxy-4-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1C=NC(=O)C2=C1C=C(OC)C(OC(C)=O)=C2 SOLQIFINSOHAQD-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- IBZKBSXREAQDTO-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)ethanamine Chemical compound COCCNCCOC IBZKBSXREAQDTO-UHFFFAOYSA-N 0.000 description 3
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 3
- VFOPWDOJVKKSOP-UHFFFAOYSA-N 6-(3-bromopropoxy)-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCBr)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VFOPWDOJVKKSOP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- XXBDUYQPZRPNMB-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-(2-imidazol-1-ylethoxy)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCN3C=NC=C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XXBDUYQPZRPNMB-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- COMSCFFBTPULJA-UHFFFAOYSA-N 1-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-3-morpholin-4-ylpropan-2-ol Chemical compound C=12C=C(OCC(O)CN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 COMSCFFBTPULJA-UHFFFAOYSA-N 0.000 description 2
- FBDKONZGCAAZJK-UHFFFAOYSA-N 3-chloro-n,n-diethylpropan-1-amine;hydron;chloride Chemical compound Cl.CCN(CC)CCCCl FBDKONZGCAAZJK-UHFFFAOYSA-N 0.000 description 2
- WFOGDVXKFPKAIQ-UHFFFAOYSA-N 6-[2-[bis(2-methoxyethyl)amino]ethoxy]-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCN(CCOC)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 WFOGDVXKFPKAIQ-UHFFFAOYSA-N 0.000 description 2
- JXDDYWNTKTYLCD-UHFFFAOYSA-N 6-[3-(diethylamino)propoxy]-n-(3,4-difluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(F)=C1 JXDDYWNTKTYLCD-UHFFFAOYSA-N 0.000 description 2
- OKZIRNNFVQCDSA-UHFFFAOYSA-N 6-hydroxy-7-methoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(O)C(OC)=CC2=N1 OKZIRNNFVQCDSA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- QRIMOJCHBRNQII-UHFFFAOYSA-N n-(2,4-difluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F QRIMOJCHBRNQII-UHFFFAOYSA-N 0.000 description 2
- SCLNZCBZYOKZJY-UHFFFAOYSA-N n-(3,4-difluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 SCLNZCBZYOKZJY-UHFFFAOYSA-N 0.000 description 2
- OOSIXUJCRGYBQJ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[2-(diethylamino)ethoxy]-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 OOSIXUJCRGYBQJ-UHFFFAOYSA-N 0.000 description 2
- CBVZLUIKUXDQLU-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[2-(dimethylamino)ethoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 CBVZLUIKUXDQLU-UHFFFAOYSA-N 0.000 description 2
- QXZNYTGAAOAYAM-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-piperidin-1-ylethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QXZNYTGAAOAYAM-UHFFFAOYSA-N 0.000 description 2
- WZAKDDWPQKWRTD-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(oxiran-2-ylmethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCC3OC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 WZAKDDWPQKWRTD-UHFFFAOYSA-N 0.000 description 2
- UEWRHTSERXIBRC-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCN(C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 UEWRHTSERXIBRC-UHFFFAOYSA-N 0.000 description 2
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical class N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- KEOPTZKJOKJEIM-VDNREOAASA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxyprop Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 KEOPTZKJOKJEIM-VDNREOAASA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WQRYDDUXWFSPQG-UHFFFAOYSA-N 1-(2-chloroethyl)imidazole Chemical compound ClCCN1C=CN=C1 WQRYDDUXWFSPQG-UHFFFAOYSA-N 0.000 description 1
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 1
- RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical compound ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 1
- OBOBUDMMFXRNDO-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine;hydron;chloride Chemical compound Cl.ClCCCN1CCCCC1 OBOBUDMMFXRNDO-UHFFFAOYSA-N 0.000 description 1
- UUPCYQIIQHSPKR-UHFFFAOYSA-N 1-(3-chloropropyl)pyrrolidine;hydrochloride Chemical compound Cl.ClCCCN1CCCC1 UUPCYQIIQHSPKR-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 1
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylamino-1-chloro-ethane hydrochloride Natural products CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical class C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- PQECODMSWJOUAT-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine;hydrochloride Chemical compound [Cl-].ClCCC[NH+]1CCOCC1 PQECODMSWJOUAT-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- ZQNGVCMAUCDUAJ-UHFFFAOYSA-N 4-[3-(2-methoxyquinazolin-6-yl)oxypropyl]morpholine Chemical compound C1=CC2=NC(OC)=NC=C2C=C1OCCCN1CCOCC1 ZQNGVCMAUCDUAJ-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- DMSRMHGCZUXCMJ-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(OC)C(OC)=CC2=N1 DMSRMHGCZUXCMJ-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 101100127890 Caenorhabditis elegans let-23 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- LARQSUYOQVLXDB-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-6-[3-(1H-imidazol-2-yl)propoxy]-7-methoxyquinazolin-4-amine Chemical compound ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCC=2NC=CN2)OC)C=CC1F LARQSUYOQVLXDB-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 1
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- ZRUSJEVFAQGVNB-UHFFFAOYSA-N S(=O)(=O)(O)OS(=O)(=O)O.ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F Chemical compound S(=O)(=O)(O)OS(=O)(=O)O.ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F ZRUSJEVFAQGVNB-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 101100429091 Xiphophorus maculatus xmrk gene Proteins 0.000 description 1
- IFNQTATWQFILMW-UHFFFAOYSA-N [4-(2,4-difluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F IFNQTATWQFILMW-UHFFFAOYSA-N 0.000 description 1
- XTDALRRLNKMRLD-UHFFFAOYSA-N [4-(3,4-difluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 XTDALRRLNKMRLD-UHFFFAOYSA-N 0.000 description 1
- RBFWFFFXYPQXHG-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 RBFWFFFXYPQXHG-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010060350 arginyl-arginyl-leucyl-isoleucyl-glutamyl-aspartyl-alanyl-glutamyl-tyrosyl-alanyl-alanyl-arginyl-glycine Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- IMCCZKHIPVEUEI-UHFFFAOYSA-N n,n-difluoroaniline Chemical compound FN(F)C1=CC=CC=C1 IMCCZKHIPVEUEI-UHFFFAOYSA-N 0.000 description 1
- JUBFKEWLPTXFBA-UHFFFAOYSA-N n-(2,4-difluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F JUBFKEWLPTXFBA-UHFFFAOYSA-N 0.000 description 1
- MEDBJFRRWZWOFV-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-(3-imidazol-1-ylpropoxy)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN3C=NC=C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 MEDBJFRRWZWOFV-UHFFFAOYSA-N 0.000 description 1
- OOSLLKQMGOLSHO-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OOSLLKQMGOLSHO-UHFFFAOYSA-N 0.000 description 1
- OHAYARNLYSPHOJ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OHAYARNLYSPHOJ-UHFFFAOYSA-N 0.000 description 1
- YYVGAKQEJHTNFP-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YYVGAKQEJHTNFP-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-BJUDXGSMSA-N potassium-38 Chemical compound [38K] ZLMJMSJWJFRBEC-BJUDXGSMSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
A példa száma | ICJ0, pmol | |
(a) vizsgálat | (b) vizsgálat vizsgálat | |
1. | 0,02 | 0,1 |
2. | 0,09 | 0,7 |
3. | 0,01 | 0,4 |
4. | 0,01 | 0,1 |
5. | 0,06 | 0,2 |
6. | 0,01 | 0,1 |
7. | 0,09 | 0,3 |
8. | 0,48 | 0,9 |
9. | 0,01 | 0,1 |
12. | 0,06 | 0,16 |
13. | 0,07 | 0,12 |
14. | 0,67 | 0,3 |
15. | 0,07 | 0,64 |
17. | 0,05 | 0,15 |
18. | 0,27 | 0,39 |
19. | 0,52 | 0,45 |
20. | 0,67 | 0,55 |
21. | 0,08 | 0,12 |
22. | 0,1 | 0,19 |
23. | 0,08 | 0,16 |
Hatóanyag | 100 | mg/tabl. |
Laktóz (Ph. Eur. minőségű) | 182,75 | >9 |
Kroszkarmellóz-nátrium | 12,0 | 99 |
Kukoricakeményítő | ||
(5 tömeg/térfogat%-os pép) | 2,25 | >9 |
Magnézium-sztearát | 3,0 | 99 |
(b) Tabletta | ||
Hatóanyag | 50 | mg/tabl. >9 |
Laktóz (Ph. Eur. minőségű) | 223,75 | |
Kroszkarmellóz-nátrium | 6,0 | 99 |
Kukoricakeményítő | 15,0 | 99 |
Poli(vinil-pirrolidon) | 2,25 | 99 |
Magnézium-sztearát | 3,0 | 99 |
(c) Tabletta | ||
Hatóanyag | 1,0 | mg/tabl. |
Laktóz (Ph. Eur. minőségű) | 93,25 | 99 |
Kroszkarmellóz-nátrium | 4,0 | 99 |
Kukoricakeményítő | ||
(5 tömeg/térfogat%-os pép) | 0,75 | 99 |
Magnézium-sztearát | 1,0 | 99 |
(d) Kapszula | ||
Hatóanyag | 10 | mg/kapsz |
Laktóz (Ph. Eur. minőségű) | 488,5 | 99 |
Magnézium-sztearát | 1,5 | 99 |
Hatóanyag | 5,0 tömeg/térf.% |
1 mólos nátrium-hidroxid-oldat | 15,0 |
0,1 mólos sósavoldat | |
(7,6-es pH-érték beállításához) | |
Polietilénglikol (M=400) | 4,5 |
Hatóanyag | 1,0 | tömeg/térf.% |
Nátrium-foszfát (BP minőségű) | 3,6 | 99 |
0,1 mólos nátrium-hidroxid-oldat | 15,0 | térf./térf.% |
Injekciós célokra alkalmas víz ad 100% | ||
(g) 1 mg/ml hatóanyagtartalmú pH 6- | ra pufferolt | |
injekció | ||
Hatóanyag | 0,1 | tömeg/térf.% |
Nátrium-foszfát (BP minőségű) | 2,26 | 99 |
Citromsav | 0,38 | 99 |
Polietilénglikol (M=400) | 3,5 | |
Injekciós célokra alkalmas víz ad 100% |
Claims (14)
- SZABADALMI IGÉNYPONTOK1. (I) általános képletű kinazolinszármazékok és gyógyászatilag alkalmazható sóik - a képletben (R2)n 3’-fluor-4’-klór- vagy 3’-klór-4’-fluor-csoportkombinációt jelent, ésR1 2-(dimetil-amino)-etoxi-, 2-(dietil-amino)-etoxi-, 3(dimetil-amino)-propoxi-, 3-(dietil-amino)-propoxi-, 2(pirrolidin-l-il)-etoxi-, 3-(pirrolidin-l-il)-propoxi-, 2piperidino-etoxi-, 3-piperidino-propoxi-, 2-morfoliηο-etoxi-, 3-morfolino-propoxi-, 2-(4-metil-piperazinl-il)-etoxi-, 2-(imidazol-l-il)-etoxi-, 3-(imidazol-l-il)propoxi-, 2-[di(2-metoxi-etil)-amino]-etoxi- vagy 3morfolino-2-hidroxi-propoxi-csoportot jelent.
- 2. Az 1. igénypontban feltüntetett (I) általános képletnek megfelelő kinazolinszármazékok és gyógyászatilag alkalmazható savaddíciós sóik - a képletben (R2)n 3’,4’-difluor-, 3’,4’-diklór-, 3’-fluor-4’-klórvagy 3’-klór-4’-fluor-csoportkombinációt jelent, ésR1 3-morfolino-propoxi-csoportot jelent.
- 3. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-[2-(pirrolidin-l-il)-etoxi]-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 4. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-(2-morfolino-etoxi)-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 5. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-[3-(dietil-amino)-propoxi]-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 6. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-[3-(pirrolidin-l-il)-propoxi]-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 7. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-[3-(dimetil-amino)-propoxi]-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 8. A 2. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’,4’-difluor-anilino)-7-metoxi-6-(3-morfolino-propoxi)-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 9. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-(3-piperidino-propoxi)-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 10. Az 1. igénypont szerinti (I) általános képletű vegyületek körébe tartozó 4-(3’-klór-4’-fluor-anilino)-7metoxi-6-(3-morfolino-propoxi)-kinazolin és gyógyászatilag alkalmazható savaddíciós sói.
- 11. A 10. igénypont szerinti (I) általános képletű vegyület hidrokloridja.
- 12. Eljárás az 1-11. igénypontok bármelyike szerinti (I) általános képletű kinazolinszármazékok és gyógyászatilag alkalmazható sóik előállítására, azzal jellemezve, hogya) egy (II) általános képletű kinazolinvegyületet egy (III) általános képletű anilinvegyülettel reagáltatunk - a képletekben R1 és (R2)„ jelentése az 1. és 2. igénypontban megadott, és Z kilépőatomot vagy csoportot jelent -, vagyb) R1 helyén aminoszubsztituált etoxi- vagy propoxicsoportot tartalmazó (I) általános képletű vegyületek előállítására egy megfelelő, R1 helyén hidroxicsoportot tartalmazó (I) általános képletű kinazolinszármazékot alkilezünk, vagyc) R1 helyén aminoszubsztituált etoxi- vagy propoxicsoportot tartalmazó (I) általános képletű vegyületek előállítására egy megfelelő, R1 helyén hidroxi-etoxivagy -propoxi-csoportot tartalmazó (I) általános képletű kinazolinvegyületet vagy reakcióképes származékát a megfelelő aminnal reagáltatjuk, vagyd) R1 helyén 3-morfolino-2-hidroxi-propoxicsoportot tartalmazó (I) általános képletű vegyületek előállítására egy megfelelő, R1 helyén 2,3-epoxi-propoxi-csoportot tartalmazó (I) általános képletű vegyületet morfolinnal reagáltatunk, és kívánt esetben egy (I) általános képletű vegyületet ismert módon gyógyászatilag alkalmazható sójává alakítunk.
- 13. Gyógyászati készítmény, azzal jellemezve, hogy hatóanyagként az 1-11. igénypontok bármelyike szerinti (I) általános képletű kinazolinszármazékot vagy gyógyászatilag alkalmazható sóját tartalmazza, gyógyászatilag alkalmazható hígító-, hordozó- és/vagy egyéb segédanyagokkal együtt.
- 14. Az 1-11. igénypontok bármelyike szerinti (I) általános képletű kinazolinszármazékok vagy gyógyászatilag alkalmazható sóik felhasználása meleg vérűeken antiproliferatív hatást kiváltó gyógyszerkészítmények előállítására.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9508538.7A GB9508538D0 (en) | 1995-04-27 | 1995-04-27 | Quinazoline derivatives |
PCT/GB1996/000961 WO1996033980A1 (en) | 1995-04-27 | 1996-04-23 | Quinazoline derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP9802839A2 HUP9802839A2 (hu) | 1999-03-29 |
HUP9802839A3 HUP9802839A3 (en) | 2001-02-28 |
HU223313B1 true HU223313B1 (hu) | 2004-05-28 |
Family
ID=10773597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9802839A HU223313B1 (hu) | 1995-04-27 | 1996-04-23 | Kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
Country Status (39)
Country | Link |
---|---|
US (1) | US5770599A (hu) |
EP (1) | EP0823900B1 (hu) |
JP (1) | JP3040486B2 (hu) |
KR (1) | KR100296656B1 (hu) |
CN (1) | CN1100046C (hu) |
AR (1) | AR003944A1 (hu) |
AT (1) | ATE198329T1 (hu) |
AU (1) | AU699163B2 (hu) |
BG (1) | BG62730B1 (hu) |
BR (1) | BRPI9608082B8 (hu) |
CA (1) | CA2215732C (hu) |
CZ (1) | CZ288489B6 (hu) |
DE (2) | DE69611361T2 (hu) |
DK (1) | DK0823900T3 (hu) |
EE (1) | EE03482B1 (hu) |
EG (1) | EG24134A (hu) |
ES (1) | ES2153098T3 (hu) |
FR (1) | FR09C0065I2 (hu) |
GB (1) | GB9508538D0 (hu) |
GR (1) | GR3035211T3 (hu) |
HK (1) | HK1005371A1 (hu) |
HR (1) | HRP960204B1 (hu) |
HU (1) | HU223313B1 (hu) |
IL (1) | IL118045A (hu) |
LU (1) | LU91631I2 (hu) |
MY (1) | MY114425A (hu) |
NL (1) | NL300429I1 (hu) |
NO (2) | NO309472B1 (hu) |
NZ (1) | NZ305444A (hu) |
PL (1) | PL189182B1 (hu) |
PT (1) | PT823900E (hu) |
RO (1) | RO117849B1 (hu) |
RU (1) | RU2153495C2 (hu) |
SI (1) | SI0823900T1 (hu) |
SK (1) | SK282236B6 (hu) |
TW (1) | TW436486B (hu) |
UA (1) | UA52602C2 (hu) |
WO (1) | WO1996033980A1 (hu) |
ZA (1) | ZA963358B (hu) |
Families Citing this family (703)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
TW321649B (hu) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
WO1996033977A1 (en) * | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DK1011648T4 (da) † | 1997-08-15 | 2005-10-24 | Cephalon Inc | Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US7354894B2 (en) * | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
CZ2001584A3 (cs) | 1998-08-18 | 2002-06-12 | The Regents Of The University Of California | Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R |
DE69924500T2 (de) * | 1998-08-21 | 2006-02-09 | Parker Hughes Institute, St. Paul | Chinazolinderivate |
AU6159499A (en) | 1998-09-29 | 2000-04-17 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
JP2002530350A (ja) * | 1998-11-20 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 血管障害を処置するためのEphレセプターのアンタゴニストおよびアゴニストについての使用 |
AU3281600A (en) | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PL365999A1 (en) * | 1999-05-14 | 2005-01-24 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
HUP0201900A3 (en) | 1999-06-21 | 2003-02-28 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
CN100376567C (zh) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
WO2002011677A2 (en) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
EP1326860A1 (en) * | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives |
ATE399766T1 (de) | 2000-10-20 | 2008-07-15 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische heterozyklen |
DE10206505A1 (de) * | 2002-02-16 | 2003-08-28 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
AU2002217999A1 (en) * | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
PT2269603E (pt) | 2001-02-19 | 2015-09-09 | Novartis Ag | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
JP4477303B2 (ja) | 2001-05-16 | 2010-06-09 | ノバルティス アーゲー | N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
EP1408980A4 (en) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | NEW QUINAZOLINES AND THEIR USE |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
ATE533750T1 (de) | 2002-02-06 | 2011-12-15 | Ube Industries | Verfahren zur herstellung einer 4- aminochinazolinverbindung |
GB0204392D0 (en) * | 2002-02-26 | 2002-04-10 | Astrazeneca Ab | Pharmaceutical compound |
RU2318518C2 (ru) * | 2002-02-26 | 2008-03-10 | Астразенека Аб | Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием |
US7612077B2 (en) * | 2002-02-26 | 2009-11-03 | Astrazeneca Ab | Crystalline forms of the anti-cancer compound ZD1839 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE60311788T2 (de) * | 2002-04-16 | 2007-11-22 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
CN1652757B (zh) | 2002-05-16 | 2012-02-08 | 诺瓦提斯公司 | Edg受体结合剂在癌症中的应用 |
US20040048887A1 (en) * | 2002-07-09 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
PL214010B1 (pl) | 2002-07-15 | 2013-06-28 | Genentech Inc | Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala |
GB0221245D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
NZ540092A (en) | 2002-11-20 | 2007-06-29 | Array Biopharma Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
US20060167026A1 (en) * | 2003-01-06 | 2006-07-27 | Hiroyuki Nawa | Antipsychotic molecular-targeting epithelial growth factor receptor |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
GB0302882D0 (en) * | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
AU2004220525B2 (en) * | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
DE10326186A1 (de) | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US20070036795A1 (en) | 2003-06-09 | 2007-02-15 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
CN103880955A (zh) | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
WO2005012290A1 (en) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
WO2005026156A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
CA2538884C (en) * | 2003-09-16 | 2010-09-21 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
EP1667992B1 (en) * | 2003-09-19 | 2007-01-24 | Astrazeneca AB | Quinazoline derivatives |
JP2007505878A (ja) * | 2003-09-19 | 2007-03-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0414735A (pt) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP1697384B1 (en) | 2003-12-18 | 2008-04-02 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
US20050221501A1 (en) * | 2003-12-24 | 2005-10-06 | Arnot Kate I | Dissolution method |
WO2005070909A1 (en) * | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | An improved process for the preparation of gefitinib |
WO2005075439A1 (en) | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
KR20070034465A (ko) | 2004-03-12 | 2007-03-28 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
EP2287194B1 (en) * | 2004-03-12 | 2016-10-26 | Vasgene Therapeutics, Inc. | Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
WO2005097137A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
KR101289774B1 (ko) | 2004-03-31 | 2013-08-07 | 다나-파버 캔서 인스티튜트 인크. | 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법 |
CN1964970B (zh) | 2004-04-07 | 2011-08-03 | 诺瓦提斯公司 | Iap的抑制剂 |
PT1746999E (pt) * | 2004-05-06 | 2012-01-11 | Warner Lambert Co | 4-fenilamino-quinazolin-6-il-amidas |
US8080577B2 (en) | 2004-05-06 | 2011-12-20 | Bioresponse, L.L.C. | Diindolylmethane formulations for the treatment of leiomyomas |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
KR20070053205A (ko) | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 의약 조성물 |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
EP1799713B1 (en) * | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
NI200700147A (es) * | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
JP4881875B2 (ja) | 2004-12-14 | 2012-02-22 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのピラゾロピリミジン化合物 |
ATE497762T1 (de) | 2004-12-30 | 2011-02-15 | Bioresponse Llc | Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus |
DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
PL1846030T3 (pl) | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
MX2007008810A (es) | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
PL1848414T3 (pl) | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
US20090155247A1 (en) * | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
WO2006090413A1 (en) * | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Novel crystalline form of gefitinib and a process for its preparation |
UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
MX2007010399A (es) | 2005-02-26 | 2007-09-25 | Astrazeneca Ab | Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina. |
EP1859793B1 (en) | 2005-02-28 | 2011-04-20 | Eisai R&D Management Co., Ltd. | Novel combinational use of a sulfonamide compound in the treatment of cancer |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
AU2006235487B2 (en) * | 2005-04-12 | 2011-12-22 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
DK1871347T3 (en) | 2005-04-19 | 2016-11-28 | Novartis Ag | pharmaceutical composition |
WO2006119673A1 (fr) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale |
WO2006119676A1 (fr) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale |
WO2006119674A1 (fr) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale |
PL1885187T3 (pl) | 2005-05-13 | 2014-03-31 | Novartis Ag | Sposoby leczenia lekoopornego raka |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP2009501141A (ja) | 2005-06-17 | 2009-01-15 | イムクローン システムズ インコーポレイテッド | 転移性骨癌の治療のための受容体アンタゴニスト |
RU2447889C2 (ru) * | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
ES2370054T3 (es) | 2005-08-24 | 2011-12-12 | Bristol-Myers Squibb Company | Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico. |
CN1300118C (zh) * | 2005-08-25 | 2007-02-14 | 江苏吴中苏药医药开发有限责任公司 | 4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-(3-吗啉丙氧基)喹唑啉的制备方法 |
CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
WO2007034144A1 (en) | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
EP1937291A2 (en) * | 2005-09-23 | 2008-07-02 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment of prevention of viral infections |
PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
SI2275103T1 (sl) | 2005-11-21 | 2014-07-31 | Novartis Ag | mTor inhibitorji pri zdravljenju endokrinih tumorjev |
WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
US7977346B2 (en) * | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
RU2452492C2 (ru) | 2006-04-05 | 2012-06-10 | Новартис Аг | КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА |
CA2645633A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
BRPI0710510A2 (pt) | 2006-04-19 | 2011-08-16 | Novartis Ag | compostos indazol e processos para inibição de cdc7 |
AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
US20090317489A1 (en) | 2006-05-09 | 2009-12-24 | Hanspeter Nick | Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof |
EP2036557B1 (en) * | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
JPWO2008001956A1 (ja) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
WO2008006884A2 (en) * | 2006-07-13 | 2008-01-17 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
ES2457072T3 (es) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
EP2061469B8 (en) * | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
EP2386655B1 (en) | 2006-09-12 | 2014-11-19 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker |
AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008046242A1 (fr) * | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
US8586621B2 (en) | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
KR20090091119A (ko) * | 2006-10-27 | 2009-08-26 | 얀센 파마슈티카 엔.브이. | 뇌암을 치료하거나 예방하기 위한 mt 키나아제 저해제의 용도 |
US7851623B2 (en) | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CA2670730A1 (en) * | 2006-12-13 | 2008-06-26 | Gilead Sciences, Inc. | Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
US7759344B2 (en) | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
JP5377332B2 (ja) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法 |
EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
WO2008121346A1 (en) * | 2007-03-30 | 2008-10-09 | Massachusetts Institute Of Technology | Methods for identifying compounds that modulate neurotrophic factor signaling |
CA2683694A1 (en) | 2007-04-16 | 2008-10-23 | Cipla Limited | Process for the preparation of gefitinib |
DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2435454T3 (es) * | 2007-06-21 | 2013-12-19 | Janssen Pharmaceutica, N.V. | Indolin-2-onas y aza-indolin-2-onas |
EP2185562B1 (en) | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
CN102083861B (zh) * | 2007-08-13 | 2016-04-13 | 瓦斯基因治疗公司 | 使用结合EphB4的人源化抗体的癌症治疗 |
CA2696761C (en) | 2007-08-21 | 2017-02-14 | Amgen Inc. | Human c-fms antigen binding proteins |
AU2008299896B2 (en) | 2007-09-10 | 2012-02-02 | Curis, Inc. | Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ,インコーポレイティド | ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物 |
US20100226919A1 (en) * | 2007-10-19 | 2010-09-09 | Pharma Mar, S.A. | Antitumoral Treatments |
WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
MY150054A (en) * | 2007-10-29 | 2013-11-29 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
AU2008325608B2 (en) | 2007-11-09 | 2013-03-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
EP2217227B1 (en) * | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
AU2008321382A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
US20110053991A1 (en) * | 2007-11-19 | 2011-03-03 | Gore Lia | Treatment of Histone Deacetylase Mediated Disorders |
UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
ES2437595T3 (es) | 2007-12-20 | 2014-01-13 | Novartis Ag | Derivados de tiazol usados como inhibidores de la PI 3 quinasa |
DK3012251T3 (en) | 2008-01-18 | 2017-10-09 | Natco Pharma Ltd | PROCEDURE FOR PREPARATION 6,7-DIALCOXY-QUINAZOLINE DERIVATIVES |
WO2009094216A1 (en) | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
EP2248804A4 (en) * | 2008-01-29 | 2014-09-10 | Eisai R&D Man Co Ltd | COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
US20100323021A1 (en) * | 2008-01-30 | 2010-12-23 | Pharma Mar, S.A. | Antitumoral treatments |
EA019709B1 (ru) | 2008-02-07 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Спирогетероциклы и их применение в качестве лекарственных средств |
KR20100131446A (ko) * | 2008-03-05 | 2010-12-15 | 노파르티스 아게 | Egfr 의존성 질환 또는 egfr 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |
US20110015135A1 (en) * | 2008-03-07 | 2011-01-20 | Pharma Mar S.A. | Antitumoral Treatments |
EP2268612B1 (en) | 2008-03-24 | 2014-08-20 | Novartis AG | Arylsulfonamide-based matrix metalloprotease inhibitors |
CN101544609A (zh) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
CN102036955B (zh) | 2008-03-26 | 2013-03-27 | 诺瓦提斯公司 | 脱乙酰酶b的异羟肟酸盐为基础的抑制剂 |
CA2723989C (en) | 2008-05-13 | 2017-04-25 | Astrazeneca Ab | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
EP2615183B1 (en) | 2008-05-14 | 2014-10-08 | Genomic Health, Inc. | Predictors of patient response to treatment with EGF receptor inhibitors |
CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
DE102008031040A1 (de) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Iressa zur Anwendung in der Organtransplantation |
CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
CN101367793B (zh) * | 2008-09-26 | 2013-09-11 | 中国科学院广州生物医药与健康研究院 | 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类 |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
US8710104B2 (en) | 2008-11-07 | 2014-04-29 | Triact Therapeutics, Inc. | Catecholic butanes and use thereof for cancer therapy |
WO2010065444A1 (en) * | 2008-12-01 | 2010-06-10 | University Of Central Florida Research Foundation, Inc. | Drug composition cytotoxic for pancreatic cancer cells |
AU2009335887A1 (en) | 2008-12-18 | 2011-06-30 | Novartis Ag | New salts |
PE20120336A1 (es) | 2008-12-18 | 2012-04-30 | Novartis Ag | Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-triflouro-metil-benciloxi-imino)-etil)-2-etil-bencil]-azetidin-3-carboxilico |
BRPI0922457A2 (pt) | 2008-12-18 | 2015-12-15 | Novartis Ag | forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico" |
TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型 |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
WO2010098367A1 (en) | 2009-02-25 | 2010-09-02 | Banyu Pharmaceutical Co.,Ltd. | Pyrimidopyrimidoindazole derivative |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8481503B2 (en) | 2009-03-06 | 2013-07-09 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an AKT inhibitor and other anticancer agents |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
WO2010120386A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
DK2445903T3 (da) | 2009-06-26 | 2014-06-23 | Novartis Ag | 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
DK2451445T3 (da) | 2009-07-06 | 2019-06-24 | Boehringer Ingelheim Int | Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens |
US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
BR112012008075A2 (pt) | 2009-08-26 | 2016-03-01 | Novartis Ag | compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4 |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
EP2496575B1 (en) | 2009-11-04 | 2014-04-30 | Novartis AG | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
EP2498817A2 (en) | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
BR112012012210B8 (pt) | 2009-11-23 | 2021-05-25 | Cerulean Pharma Inc | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano |
US20120289501A1 (en) | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
BR112012017269A2 (pt) | 2010-01-12 | 2016-05-03 | Hoffmann La Roche | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
CN102146060B (zh) * | 2010-02-09 | 2013-07-03 | 陕西师范大学 | 制备吉非替尼及其中间体的方法 |
MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
WO2011107664A1 (en) | 2010-03-04 | 2011-09-09 | Hospital District Of Southwest Finland | Method for selecting patients for treatment with an egfr inhibitor |
CN102869359A (zh) | 2010-03-17 | 2013-01-09 | 弗·哈夫曼-拉罗切有限公司 | 咪唑并吡啶和嘌呤化合物、组合物和使用方法 |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
JP2013528357A (ja) | 2010-03-29 | 2013-07-11 | ザイムワークス,インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Egfr與vegfr-2雙重抑制劑及其用途與製法 |
KR20130058672A (ko) | 2010-04-16 | 2013-06-04 | 제넨테크, 인크. | PI3K/AKT 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 FOXO3a |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
EP2582681A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
RU2013114360A (ru) | 2010-08-31 | 2014-10-10 | Дженентек, Инк. | Биомаркеры и способы лечения |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
WO2012066061A1 (en) | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
KR20130121886A (ko) | 2010-11-24 | 2013-11-06 | 글락소 그룹 리미티드 | Hgf를 표적으로 하는 다중특이적 항원 결합 단백질 |
JP2014500308A (ja) | 2010-12-21 | 2014-01-09 | ノバルティス アーゲー | Vps34阻害剤としてのビヘテロアリール化合物 |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
US8987257B2 (en) | 2011-01-31 | 2015-03-24 | Novartis Ag | Heterocyclic derivatives |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
BR112013022552B1 (pt) | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
JP2014507465A (ja) | 2011-03-08 | 2014-03-27 | ノバルティス アーゲー | フルオロフェニル二環式ヘテロアリール化合物 |
US8609818B2 (en) | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
US9295676B2 (en) | 2011-03-17 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of EGFR |
US9321759B2 (en) | 2011-03-17 | 2016-04-26 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
EP2688887B1 (en) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
CN103649073B (zh) | 2011-04-28 | 2016-04-13 | 诺瓦提斯公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
MX2013014398A (es) | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
CN103608349A (zh) | 2011-06-27 | 2014-02-26 | 诺瓦提斯公司 | 四氢-吡啶并-嘧啶衍生物的固体形式和盐 |
SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
CN103889976A (zh) | 2011-08-12 | 2014-06-25 | 弗·哈夫曼-拉罗切有限公司 | 吲唑化合物、组合物及使用方法 |
JP5944994B2 (ja) | 2011-08-12 | 2016-07-05 | オメロス コーポレーション | 抗fzd10モノクローナル抗体およびそれらの使用方法 |
WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
MX2014002436A (es) | 2011-08-31 | 2014-05-27 | Genentech Inc | Marcadores de diagnostico. |
CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
CN103827115A (zh) | 2011-09-20 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | 咪唑并吡啶化合物、组合物和使用方法 |
CN103012290B (zh) * | 2011-09-28 | 2015-05-13 | 齐鲁制药有限公司 | 一种高纯度吉非替尼的制备方法 |
JP2014531213A (ja) | 2011-09-30 | 2014-11-27 | ジェネンテック, インコーポレイテッド | 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答 |
EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
MX340452B (es) | 2011-10-28 | 2016-07-08 | Novartis Ag | Novedosos derivados de purina y su uso en el tratamiento de enfermedades. |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
CN103102342B (zh) * | 2011-11-14 | 2014-10-29 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
CN103102345B (zh) * | 2011-11-14 | 2015-06-03 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN103130729B (zh) * | 2011-12-05 | 2015-07-15 | 齐鲁制药有限公司 | 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法 |
CN103172576B (zh) * | 2011-12-21 | 2015-08-05 | 沈阳药科大学 | 吉非替尼的苹果酸加成盐及其制备和应用 |
JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
AU2012355619A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
AU2013214254B2 (en) | 2012-01-31 | 2016-04-21 | Novartis Ag | Method of treating cancer |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US20140170159A9 (en) | 2012-03-08 | 2014-06-19 | Ge Wei | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013143057A1 (zh) | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
CN104220457A (zh) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | 涉及her3抑制剂的诊断和治疗 |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
KR20150009540A (ko) | 2012-05-16 | 2015-01-26 | 노파르티스 아게 | Pi-3 키나제 억제제에 대한 투여 요법 |
JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
KR101457453B1 (ko) * | 2012-05-31 | 2014-11-04 | 주식회사 종근당 | 게피티닙의 제조방법 및 이의 제조에 사용되는 중간체 |
EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
WO2014016848A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
US9738643B2 (en) | 2012-08-06 | 2017-08-22 | Duke University | Substituted indazoles for targeting Hsp90 |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
EP2937337A4 (en) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
CN103073509A (zh) * | 2012-12-31 | 2013-05-01 | 广东先强药业有限公司 | 一类喹唑啉衍生物的制备方法 |
CN103910690A (zh) * | 2013-01-06 | 2014-07-09 | 上海科胜药物研发有限公司 | 一种吉非替尼新晶型及其制备方法 |
WO2014108858A1 (en) | 2013-01-10 | 2014-07-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Fatty acid synthase inhibitors |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
EP2964260A2 (en) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Methods of treating and preventing cancer drug resistance |
PE20152000A1 (es) | 2013-03-06 | 2016-01-22 | Astrazeneca Ab | Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico |
MX2015011898A (es) | 2013-03-13 | 2016-05-05 | Genentech Inc | Compuestos de pirazolo y usos de los mismos. |
CA2905070A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
JP2016515132A (ja) | 2013-03-14 | 2016-05-26 | ジェネンテック, インコーポレイテッド | Mek阻害剤化合物のher3/egfr阻害剤化合物との組み合わせ及び使用方法 |
BR112015022993B1 (pt) | 2013-03-14 | 2021-12-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes |
JP2016520528A (ja) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | 癌の治療及び抗癌剤耐性の防止方法 |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
US20160051556A1 (en) | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
CN103304491A (zh) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | 一种吉非替尼的制备方法 |
KR20150001936A (ko) * | 2013-06-28 | 2015-01-07 | 제일약품주식회사 | 게피티닙의 신규한 결정형 및 이의 제조방법 |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
TW201536291A (zh) * | 2013-08-02 | 2015-10-01 | Cephalon Inc | 單獨使用AXL/cMET抑制劑或與其它藥劑組合使用以治療多種癌症之方法 |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
KR20160049003A (ko) | 2013-09-05 | 2016-05-04 | 제넨테크, 인크. | 항증식성 화합물 |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
EA201600252A1 (ru) | 2013-09-12 | 2017-05-31 | Галозим, Инк. | Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования |
CA2920059A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
AR097894A1 (es) | 2013-10-03 | 2016-04-20 | Hoffmann La Roche | Inhibidores terapéuticos de cdk8 o uso de los mismos |
KR20160070136A (ko) | 2013-10-18 | 2016-06-17 | 제넨테크, 인크. | 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
CN105979947A (zh) | 2013-12-06 | 2016-09-28 | 诺华股份有限公司 | α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案 |
EP3083686B2 (en) | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2015128837A1 (en) | 2014-02-26 | 2015-09-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
US10000469B2 (en) | 2014-03-25 | 2018-06-19 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
SG11201608106PA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
PE20211291A1 (es) | 2014-03-31 | 2021-07-20 | Genentech Inc | Anticuerpos anti-ox40 y metodos de uso |
WO2015153345A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015170345A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | Pharmaceutical cocrystals of gefitinib |
RU2577518C2 (ru) * | 2014-06-02 | 2016-03-20 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
US9617227B2 (en) | 2014-06-10 | 2017-04-11 | Scinopharm (Changshu) Pharmaceuticals, Ltd. | Process of preparing a quinazoline derivative |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
TWI721954B (zh) | 2014-08-28 | 2021-03-21 | 日商衛材R&D企管股份有限公司 | 高純度喹啉衍生物及其生產方法 |
WO2016036873A1 (en) | 2014-09-05 | 2016-03-10 | Genentech, Inc. | Therapeutic compounds and uses thereof |
TWI567063B (zh) * | 2014-09-05 | 2017-01-21 | 國立交通大學 | 用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途 |
EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
WO2016057924A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
ES2855075T3 (es) | 2014-10-17 | 2021-09-23 | Novartis Ag | Combinación de ceritinib con un inhibidor de EGFR |
RU2017119231A (ru) | 2014-11-03 | 2018-12-06 | Дженентек, Инк. | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 |
RU2017119009A (ru) | 2014-11-03 | 2018-12-05 | Дженентек, Инк. | Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения |
CN107073126A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和tigit抑制剂的组合疗法 |
CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
ES2910659T3 (es) * | 2014-12-04 | 2022-05-13 | Delta Fly Pharma Inc | Nuevo derivado de PEG |
US20180000827A1 (en) | 2014-12-19 | 2018-01-04 | Synthon B.V. | Pharmaceutical composition comprising gefitinib |
CA2968359A1 (en) | 2014-12-23 | 2016-06-30 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
CN107223163A (zh) | 2014-12-24 | 2017-09-29 | 豪夫迈·罗氏有限公司 | 用于膀胱癌症的治疗,诊断和预后方法 |
EP3240908A2 (en) | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
JP7041515B2 (ja) | 2015-01-08 | 2022-03-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞 |
CN107406414B (zh) | 2015-01-09 | 2022-04-19 | 基因泰克公司 | 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 |
JP6889661B2 (ja) | 2015-01-09 | 2021-06-18 | ジェネンテック, インコーポレイテッド | 4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用 |
WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
KR101635724B1 (ko) * | 2015-01-28 | 2016-07-05 | 일동제약주식회사 | 게피티닙의 개선된 제조방법 |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
EP3250552B1 (en) | 2015-01-30 | 2019-03-27 | Genentech, Inc. | Therapeutic compounds and uses thereof |
RU2017128583A (ru) | 2015-02-25 | 2019-03-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ ослабления горечи хинолинового производного |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
EP3272746B1 (en) * | 2015-03-20 | 2019-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing same |
KR20180002653A (ko) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
PT3294770T (pt) | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
IL255372B (en) | 2015-05-29 | 2022-07-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
AU2016279474B2 (en) | 2015-06-16 | 2021-09-09 | Eisai R&D Management Co., Ltd. | Anticancer agent |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
CA2996233C (en) | 2015-08-26 | 2024-01-16 | Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos Iii (F.S.P. Cnio) | Condensed tricyclic compounds as protein kinase inhibitors |
CN108350605A (zh) | 2015-09-04 | 2018-07-31 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
GB201516905D0 (en) | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
RU2732591C2 (ru) | 2015-09-25 | 2020-09-21 | Дженентек, Инк. | Анти-tigit антитела и способы применения |
CN105250228B (zh) * | 2015-10-12 | 2017-10-24 | 山东罗欣药业集团股份有限公司 | 一种吉非替尼的片剂及其原料的制备方法 |
RU2018119085A (ru) | 2015-11-02 | 2019-12-04 | Новартис Аг | Схема введения ингибитора фосфатидилинозитол-3-киназы |
WO2017093942A1 (en) | 2015-12-01 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
CA3008394A1 (en) | 2015-12-16 | 2017-06-22 | Genentech, Inc. | Process for the preparation of tricyclic pi3k inhibitor compounds and methods of using the same for the treatment of cancer |
JP6871255B2 (ja) | 2015-12-30 | 2021-05-12 | シントン・ベスローテン・フェンノートシャップ | ゲフィチニブの結晶形aを製造する方法 |
CN105503748A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种吉非替尼的制备方法 |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
MX2018010361A (es) | 2016-02-29 | 2019-07-08 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
JP2019518426A (ja) | 2016-04-15 | 2019-07-04 | ジェネンテック, インコーポレイテッド | がんの診断及び治療方法 |
CN109154027A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
MX2018012492A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para monitorear y tratar el cáncer. |
SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
MA45146A (fr) | 2016-05-24 | 2021-03-24 | Constellation Pharmaceuticals Inc | Dérivés de pyrazolopyridine pour le traitement du cancer |
EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
CN106045980B (zh) * | 2016-06-03 | 2017-11-03 | 江苏开放大学 | 一种喹唑啉衍生物及其制备方法 |
CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
CN109312407A (zh) | 2016-06-08 | 2019-02-05 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
CN110072545A (zh) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性聚糖组合物及其用途 |
KR102528998B1 (ko) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | 인간 항체, 제약 조성물 및 방법 |
US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
WO2018039205A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
CN106432202B (zh) * | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
RU2019112860A (ru) | 2016-09-27 | 2020-10-30 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
MX2019003934A (es) | 2016-10-06 | 2019-07-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
TWI822055B (zh) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
KR20190134631A (ko) | 2017-03-01 | 2019-12-04 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
US9980967B1 (en) | 2017-03-16 | 2018-05-29 | National Chiao Tung University | Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma |
CA3058279A1 (en) | 2017-04-13 | 2018-10-18 | F.Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US11674962B2 (en) | 2017-07-21 | 2023-06-13 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
MX2020000903A (es) | 2017-08-11 | 2020-07-22 | Genentech Inc | Anticuerpos anti-cd8 y usos de los mismos. |
AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
CA3073073A1 (en) | 2017-09-08 | 2019-03-14 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
CA3073421A1 (en) | 2017-09-26 | 2019-04-04 | Daniel Mark COREY | Chimeric engulfment receptor molecules and methods of use |
CA3079422A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
CN109721552B (zh) * | 2017-10-30 | 2022-09-20 | 上海北卡医药技术有限公司 | 一种吉非替尼的制备方法 |
WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
EP3727387A4 (en) | 2017-12-18 | 2021-12-15 | Sterngreene, Inc. | PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS |
AU2017444054B2 (en) | 2017-12-21 | 2021-10-07 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Class of pyrimidine derivative kinase inhibitors |
US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CN111936487A (zh) | 2018-01-26 | 2020-11-13 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
CA3088127A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
CN117603138A (zh) | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
CA3092108A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2019191339A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
MX2020010241A (es) | 2018-03-28 | 2020-10-16 | Cero Therapeutics Inc | Composiciones de inmunoterapia celular y usos de las mismas. |
EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
EP3773591A4 (en) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL KINASE INHIBITORS AND THEIR USE |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CN108395410A (zh) * | 2018-05-09 | 2018-08-14 | 日照市普达医药科技有限公司 | 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用 |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
EP3797173A2 (en) | 2018-05-21 | 2021-03-31 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
MX2020014091A (es) | 2018-06-23 | 2021-05-27 | Genentech Inc | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii. |
TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
EP3823611A1 (en) | 2018-07-18 | 2021-05-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
EP3826988A4 (en) | 2018-07-24 | 2023-03-22 | Hygia Pharmaceuticals, LLC | COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER |
EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
CN113196061A (zh) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
MX2021007158A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
WO2020132648A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
JP2022513971A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
JP2022523100A (ja) | 2019-02-01 | 2022-04-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ベランタマブマフォドチンおよび抗ox40抗体を含むがんの併用治療ならびにその使用および方法 |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
SG11202108707WA (en) | 2019-02-27 | 2021-09-29 | Epiaxis Therapeutics Pty Ltd | Methods and agents for assessing t-cell function and predicting response to therapy |
JP2022521773A (ja) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | 抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬 |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
KR20220026585A (ko) | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
JP2022542319A (ja) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
JP2022547483A (ja) | 2019-09-04 | 2022-11-14 | ジェネンテック, インコーポレイテッド | Cd8結合性作用剤およびその使用 |
WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
TW202126651A (zh) | 2019-09-26 | 2021-07-16 | 美商艾克塞里克斯公司 | 吡啶酮化合物及使用方法 |
CA3151406A1 (en) | 2019-09-27 | 2021-04-01 | Raymond D. Meng | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
CA3155857A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
JP2022553857A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
CA3155922A1 (en) | 2019-11-06 | 2021-05-14 | Huang Huang | Diagnostic and therapeutic methods for treatment of hematologic cancers |
EP4055017A1 (en) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
CR20220207A (es) | 2019-11-13 | 2022-06-06 | Genentech Inc | Compuestos terapéuticos y métodos de uso |
CA3158188A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
CA3166980A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
TW202142230A (zh) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗tigit拮抗體抗體治療癌症之方法 |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
EP4122925A4 (en) * | 2020-03-17 | 2024-04-17 | Medshine Discovery Inc | PROTEOLYSIS REGULATOR AND METHOD OF USE |
EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
CN113801068A (zh) * | 2020-06-15 | 2021-12-17 | 鲁南制药集团股份有限公司 | 一种吉非替尼的有机酸盐 |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
JP2023531290A (ja) | 2020-06-30 | 2023-07-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法 |
JP2023531305A (ja) | 2020-06-30 | 2023-07-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法後の固形癌患者の再発及び/又は死亡のリスクを予測するための方法。 |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
EP4189121A1 (en) | 2020-08-03 | 2023-06-07 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
KR20230078657A (ko) | 2020-08-27 | 2023-06-02 | 에노시 테라퓨틱스 코퍼레이션 | 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물 |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
CN112321814B (zh) * | 2020-12-30 | 2021-03-23 | 广州初曲科技有限公司 | 一种吉非替尼艾地苯醌轭合物的制备及用途 |
EP4291558A1 (en) | 2021-02-12 | 2023-12-20 | F. Hoffmann-La Roche AG | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2022178205A1 (en) | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Pyridone compounds and methods of use |
EP4298114A1 (en) | 2021-02-26 | 2024-01-03 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
CA3221390A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
CN113527266A (zh) * | 2021-06-23 | 2021-10-22 | 上海健康医学院 | 一种靶向fap的双氧水响应的前药及其制备方法与应用 |
CN113336742B (zh) | 2021-06-29 | 2022-05-10 | 山东金吉利新材料有限公司 | 一种马来酸吡咯替尼中间体的合成方法 |
EP4373506A1 (en) | 2021-07-20 | 2024-05-29 | AGS Therapeutics SAS | Extracellular vesicles from microalgae, their preparation, and uses |
EP4376874A1 (en) | 2021-07-28 | 2024-06-05 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
TW202321261A (zh) | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | 選擇性kras抑制劑 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CN113845485B (zh) * | 2021-10-22 | 2023-03-14 | 湖南中医药大学 | 氨基酸衍生物及其制备方法和应用 |
TW202340212A (zh) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024030441A1 (en) | 2022-08-02 | 2024-02-08 | National University Corporation Hokkaido University | Methods of improving cellular therapy with organelle complexes |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
WO2024085242A2 (en) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Non-fouling or super stealth vesicle |
WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
DE68917485T2 (de) * | 1988-01-23 | 1995-02-09 | Kyowa Hakko Kogyo Kk | Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen. |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
DE9290018U1 (de) * | 1991-02-20 | 1993-10-14 | Pfizer | 2,4-Diaminochinazolin-Derivate zur Verbesserung der Antitumor-Aktivität |
WO1992020642A1 (en) * | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
WO1995006648A1 (en) * | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivative |
US5409000A (en) * | 1993-09-14 | 1995-04-25 | Cardiac Pathways Corporation | Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method |
GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
EP0746554A1 (en) * | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
ES2109796T3 (es) * | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (hu) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
DE19510019A1 (de) * | 1995-03-20 | 1996-09-26 | Thomae Gmbh Dr K | Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
AU5108196A (en) * | 1995-03-20 | 1996-10-08 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
DE69536015D1 (de) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
AU711592B2 (en) * | 1995-04-03 | 1999-10-14 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
WO1996033977A1 (en) * | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
KR100256707B1 (ko) * | 1995-05-12 | 2000-05-15 | 해피 페너 | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 |
EP0832073B1 (en) * | 1995-06-07 | 2002-01-16 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
BR9609617B1 (pt) * | 1995-07-06 | 2010-07-27 | derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica. | |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
-
1995
- 1995-04-27 GB GBGB9508538.7A patent/GB9508538D0/en active Pending
-
1996
- 1996-04-08 TW TW085104049A patent/TW436486B/zh not_active IP Right Cessation
- 1996-04-23 AT AT96910134T patent/ATE198329T1/de active
- 1996-04-23 WO PCT/GB1996/000961 patent/WO1996033980A1/en active IP Right Grant
- 1996-04-23 SK SK1454-97A patent/SK282236B6/sk not_active IP Right Cessation
- 1996-04-23 CN CN96193526A patent/CN1100046C/zh not_active Expired - Lifetime
- 1996-04-23 CZ CZ19973396A patent/CZ288489B6/cs not_active IP Right Cessation
- 1996-04-23 NZ NZ305444A patent/NZ305444A/xx not_active IP Right Cessation
- 1996-04-23 DE DE69611361T patent/DE69611361T2/de not_active Expired - Lifetime
- 1996-04-23 AU AU53433/96A patent/AU699163B2/en not_active Expired
- 1996-04-23 PT PT96910134T patent/PT823900E/pt unknown
- 1996-04-23 RU RU97119521/04A patent/RU2153495C2/ru active Protection Beyond IP Right Term
- 1996-04-23 DE DE122009000076C patent/DE122009000076I1/de active Pending
- 1996-04-23 KR KR1019970707511A patent/KR100296656B1/ko not_active IP Right Cessation
- 1996-04-23 HU HU9802839A patent/HU223313B1/hu active Protection Beyond IP Right Term
- 1996-04-23 EG EG35896A patent/EG24134A/xx active
- 1996-04-23 SI SI9630183T patent/SI0823900T1/xx unknown
- 1996-04-23 ES ES96910134T patent/ES2153098T3/es not_active Expired - Lifetime
- 1996-04-23 EE EE9700252A patent/EE03482B1/xx active Protection Beyond IP Right Term
- 1996-04-23 CA CA002215732A patent/CA2215732C/en not_active Expired - Lifetime
- 1996-04-23 EP EP96910134A patent/EP0823900B1/en not_active Expired - Lifetime
- 1996-04-23 UA UA97115677A patent/UA52602C2/uk unknown
- 1996-04-23 DK DK96910134T patent/DK0823900T3/da active
- 1996-04-23 JP JP8532252A patent/JP3040486B2/ja not_active Expired - Lifetime
- 1996-04-23 RO RO97-01978A patent/RO117849B1/ro unknown
- 1996-04-23 PL PL96323066A patent/PL189182B1/pl unknown
- 1996-04-23 BR BRPI9608082A patent/BRPI9608082B8/pt not_active IP Right Cessation
- 1996-04-24 AR ARP960102305A patent/AR003944A1/es unknown
- 1996-04-25 MY MYPI96001577A patent/MY114425A/en unknown
- 1996-04-25 HR HR960204A patent/HRP960204B1/xx not_active IP Right Cessation
- 1996-04-26 US US08/638,331 patent/US5770599A/en not_active Expired - Lifetime
- 1996-04-26 IL IL11804596A patent/IL118045A/en active Protection Beyond IP Right Term
- 1996-04-26 ZA ZA963358A patent/ZA963358B/xx unknown
-
1997
- 1997-10-24 NO NO974940A patent/NO309472B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102052A patent/BG62730B1/bg unknown
-
1998
- 1998-05-25 HK HK98104504A patent/HK1005371A1/xx not_active IP Right Cessation
-
2001
- 2001-01-11 GR GR20010400025T patent/GR3035211T3/el unknown
-
2009
- 2009-12-15 FR FR09C0065C patent/FR09C0065I2/fr active Active
- 2009-12-16 NO NO2009028C patent/NO2009028I1/no unknown
- 2009-12-17 LU LU91631C patent/LU91631I2/fr unknown
- 2009-12-17 NL NL300429C patent/NL300429I1/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU223313B1 (hu) | Kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
EP0824525B1 (en) | Quinazoline derivatives | |
US6015814A (en) | Quinazoline derivative | |
EP0823901B1 (en) | Quinazoline derivative | |
EP0824527B1 (en) | Quinazoline derivatives | |
JP3330706B2 (ja) | キナゾリン誘導体、その製法及びこれを含有する抗癌作用を有する医薬組成物 | |
EP0892799B1 (en) | Quinazoline derivatives | |
TW321649B (hu) | ||
EP2163546A1 (en) | Quinazoline derivatives | |
MXPA97008177A (en) | Quinazol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20040405 |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: GEFITINIB; REG. NO/DATE: EU/1/09/526/001 20090624 Spc suppl protection certif: S0900026 Filing date: 20091215 Expiry date: 20160423 |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: GEFITINIB; REG. NO/DATE: EU/1/09/526/001 20090624; FIRST REG. NO: 56154 01 20040302 Spc suppl protection certif: S0900026 Filing date: 20091215 Expiry date: 20160423 Extension date: 20190303 |